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The objective of the study was to evaluate the use of human albumin in a Brazilian university hospital, 
in compliance with the institutional protocol and other clinical guidelines, taking into account the 
therapeutic indications and the dosage regimens. Data was obtained from the pharmacy dispensing records 
of human albumin, the requests for use it and, when available, the patient’s records between January 
and October 2017. After evaluation the therapeutic indications and the dosage regimens were classified 
as “appropriate” and “inappropriate”. The analysis of 98 requests showed that, when compared to the 
institutional protocol, 54 (55.1%) requests had an inappropriate therapeutic indication. However, when 
a comparison was made between 25 medical records (54 requests) and other clinical guidelines, it was 
observed that the therapeutic indication had none classified as inappropriate. In addition, 16 (29.7%) 
requests were considered inappropriate in relation to dosage regimens. From these results, it was possible 
to conclude that although the use of human albumin in the hospital was associated to a clinical protocol, 
it was outdated. Thus, it is possible to affirm that not only the adoption of a clinical protocol, but its 
periodical updating is an important strategy to promote the rational use of drugs. 
Keywords: Albumins/drug utilization review. Health services. University Hospital/Brazil. Drugs/use.
INTRODUCTION
Human albumin (HA) is the major serum protein, 
accounting for about 50% of the total plasma circulating 
proteins. It is also the main responsible for maintaining 
intravascular oncotic pressure, accounting for at least 70% 
of it in healthy individuals (Valerio et al., 2016; Bernardi, 
Ricci, Zaccherini, 2014).
HA is a pharmaceutical product available in 
hyperosmotic concentrations (20 to 25%) for re-
establishing oncotic pressure and iso-osmotic concentration 
(5%) for plasma volume replacement (Matos, Rozenfeld, 
2005). Because HA is a blood derivative, it has limited 
availability and a manufacturing process with strict 
health and safety regulations. It is considered a safe 
product, although the potential risk of micro-organisms 
transmission or severe allergenic effects cannot be ruled 
out. As a consequence of these factors, HA is a product 
that has a high cost (Matos, Rozenfeld, 2005; Vaglio et 
al., 2014; Liumbruno et al., 2009; Casuccio et al., 2015; 
Corrêa et al., 2015).
The question of the rational use of HA in clinical 
hospital practice is still discussed today. This is because 
it is categorized as an A item in ABC analysis of most 
hospitals, compromising a significant part of hospital 
budgets. In addition, the recommendations for the use 
of HA are still very divergent, mainly because most of 
its therapeutic indications are related to physiological 
properties rather than scientific evidence of superior 
effectiveness to other therapeutic alternatives. In fact, for 
the introduction of HA into clinical practice, controlled 
studies have not been conducted to prove its effectiveness 
and safety for each of the therapeutic indications, as 
it occurs with other drugs (Matos, Rozenfeld, 2005; 
Casuccio et al., 2015; Caraceni, Tufoni, Bonavita, 2013; 
Borges Filho et al., 2010).
In 1975, the National Institute of Health (NIH) held 
a consensus conference to develop a protocol to rationalize 
the use of HA in the United States (Tullis 1977a; Tullis 
1977b). From this consensus, countries such as Australia, 
Canada, Spain, France and Italy have also established 
committees and developed clinical practice guidelines 
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or clinical protocols. Thus, the therapeutic indications 
of HA were classified as: 1) Approved indications, with 
convincing evidence; 2) Indications not approved, but 
with potential clinical benefit, most of the time with 
inconclusive evidence; 3) Indications not recommended 
(Casuccio et al., 2015; Vermeulen, Ratko, Erstad, 2010; 
Liumbruno et al., 2009; Stanford Health Care, 2017; Guy’s 
and St. Thomas’ NHS Foundation Trust, 2015; Caraceni 
et al., 2016; National Plasma Products Expert Advisory 
Group - Scotland NHS, 2016; Ontario Regional Blood 
Coordinating Network, 2012; Lyu et al., 2016).
Despite the establishment of these guidelines, the 
irrational use of HA is still very present in clinical practice. 
According to a European study published in 2013, up to 
90% of HA prescriptions in clinical practice of several 
countries are not supported by clinical evidence, guidelines, 
or practical recommendations (Caraceni et al., 2013).
In Brazil, the national guidelines for the rational 
use of HA were established by the National Agency of 
Sanitary Surveillance (ANVISA) by Directors’ Collegiate 
Resolution (RDC) No. 115, dated May 10, 2004 (Brasil, 
2004). In this guideline, indications were classified 
into: 1) Formal indications; 2) Debatable indications; 
3) Unsubstantiated indications. A study carried out in a 
quaternary hospital located in São Paulo city pointed out 
that of a total of 14,799 bottles of 20% human albumin 
consumed between January and October 2007, 4,191 
(28%) bottles were for unsubstantiated indications (Borges 
Filho et al., 2010). A similar result was found in a study 
conducted in a general hospital in the city of Rio de 
Janeiro, where the rate of the unsubstantiated indications 
represented 20.9% of the total prescriptions evaluated 
between March and June 2001 (Matos, Rozenfeld, 2005).
The economic repercussion of the irrational use of 
HA is also often pointed out in studies of the appropriate 
use of this medicine. According to a prospective 
observational study carried out in two university hospitals 
in Spain between October 1995 and March 1996, only 
8.1% of HA prescriptions were considered appropriate. 
Therefore, there was an irrational use of 2,893 bottles 
of HA with a significant financial impact (74,306 ECU) 
(Vargas et al., 1997). The irrational use of HA in a 
quaternary hospital in São Paulo resulted in a loss of R$ 
1.36 million (Borges Filho et al., 2010).
Considering that the national guideline that orientate 
the use of HA was published in 2004, the high cost of the 
drug and its relevance in clinical practice, this study aims 
to evaluate the appropriateness of requests for albumin use 
(therapeutic indication and dosing regimen) in a hospital, 
according to the institutional protocol and other clinical 
guidelines published in the last years (2007 – 2017).
MATERIAL AND METHODS
This is a cross-sectional, descriptive, retrospective 
study conducted in a Brazilian medium complexity 
university hospital.
Place of study 
The University Hospital of the University of São 
Paulo (HU-USP) is a medium complexity hospital. With 
259 beds, the hospital provides outpatient and emergency 
services to the local community of Butantã, a district 
of São Paulo city, and to the university community of 
USP (students, teachers and employees) and develops 
teaching and research activities in the healthcare field. 
The hospital has a Pediatric Emergency Room (PER) 
and an Adult Emergency Room (AER), in addition to 8 
admission units: Clinical Surgery (CS), Medical Clinic 
(MC), Maternity (MAT), Nursery (NUR), Pediatric 
Clinic (PC), Adult Intensive Care Unit (AICU), Pediatric 
Intensive Care Unit (PICU) and Neonatal Intensive Care 
Unit (NICU).
Dispensation of human albumin at HU-USP
The HA dispensing by the HU-USP Pharmacy 
Division is subject to an institutional protocol that 
was implemented in 2004 and is based on ANVISA 
RDC No. 115, dated May 10, 2004 (Brasil, 2004). 
This institutional protocol classifies the HA therapeutic 
indications as presented in Table I and does not provide 
recommendations on dosage.
According to the institutional protocol of HU-USP, 
for HA to be dispensed by the Pharmacy, the prescriber 
must submit a request form for using it. This request 
consisted of a form where the prescriber presented 
the diagnosis, the therapeutic indication, the dosage 
regimen (dose, frequency, administration route and 
treatment time) proposed for the patient. In addition, the 
prescriber marked one of the indications presented in 
Table I. The request was then evaluated by pharmacists 
and, if necessary, it was submitted for approval of the 
hospital board of directors. Then, the HA dispensing was 
electronically registered.
Inclusion and exclusion criteria 
We included all patients for who HA was requested 
between January 1, 2017 and October 31, 2017, regardless 
of age. Therefore, none patient would be excluded in 
analysis.
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Data collect
The information was obtained from the HA 
dispensing electronic record of the Pharmacy Division, the 
HA request forms, the medical records and prescriptions 
of the patients who received HA within the period defined 
by the study. 
The electronic record consisted of software 
developed by the Department of Informatics of HU-
USP, from which it was possible to extract reports on the 
consumption of HA in the hospital. From this report we 
obtained the number of bottles dispensed by the Pharmacy 
and the list of patients for whom HA was dispensed.
The data collected from the HA request forms were: 
patient identification number, admission unit, diagnosis 
and indication that would justify the use of HA, the 
proposed dosage regimen and treatment time.
From the patient identification number obtained 
in the HA request forms, we made consultations at the 
Statistical Medical Archive Service (SMAS) archives 
to analyze the patient’s records. The medical records 
were classified as unavailable if after 3 attempts in this 
sector they were not available for consultation. Patient-
related complementary information (age and weight) and 
clinical status were obtained from the patient’s records. In 
addition, the HA prescriptions were analyzed to verify the 
dosage regimen of these patients.
Analysis of the appropriate use of human albumin 
The analysis of the appropriate use of albumin was 
performed according to two criteria: therapeutic indication 
in accordance with institutional protocol - based on RDC 
No. 115, dated May 10, 2004; indication and dosage 
regimen, according to HA clinical guidelines published 
in the last years (2007 – 2017).
Institutional protocol: therapeutic indication 
Knowing that the objective of this stage is to classify 
therapeutic indications presented in the HA request forms 
as “appropriate” or “inappropriate” in relation to the 
institutional protocol, the following strategy was adopted: 
Initially, the therapeutic indications checked in 
the HA request forms were ranked according to the 
classification presented in Table I (unquestionable, 
debatable, and other indications). Indications marked 
“unquestionable” and “debatable” were classified as 
“appropriate” because they were indications where 
albumin using was supported by the institutional protocol. 
The indications marked “other” had their justifications 
analyzed because there could be a filling error. If the 
indication was described in the protocol, it would be 
classified as “appropriate”; in other situations, the 
indication was considered “inappropriate”.
Clinical protocols published in the last years: 
therapeutic indication and dosage regimen 
For this stage, a search was made to find clinical 
protocols that presented recommendations for the 
rational use of albumin. Pubmed database and Google® 
web search engine were used, applying the following 
descriptors: clinical practice guide, clinical protocol and 
albumin in English, Portuguese and Spanish languages. 
Only the documents published in the last years (2007 – 
2017) were included in the analysis. From the findings, a 
table was drawn up with the synthesis of recommendations 
for each of the therapeutic indications of HA. 
The use of HA was considered “appropriate” in 
those cases that the use reported in the medical record 
were in agreement with the recommendations found in the 
review. In cases that the conditions for the use of HA were 
recommended, the indication was considered appropriate 
only if the patient’s condition met these criteria. The use 
was classified as “inappropriate” only in those situations 
that there was no recommendation or it was contrary to 
the recommendation. In the case of the dosage regimen 
analysis, dose and proposed treatment time were main 
criteria evaluated. In this stage of analysis, data of the 
request forms and medical records were considered.
Ethical aspects 
The study was submitted to the Research Ethics 
Committee (REC) of the Faculty of Pharmaceutical 
TABLE I - HA therapeutic indications according to the 
institutional protocol of HU-USP
Unquestionable indications
Treatment of massive ascites by repeated paracentesis
After evacuation paracentesis in massive ascites
Hepatic cirrhosis and nephrotic syndrome, when there is 
diuretic-refractory edema, that pose imminent risk to patients’ 
lives (massive pleural or pericardial effusion or ascites)
Debatable indications
In patients with cirrhosis and prevalence of spontaneous 
bacterial peritonitis
Newborn hyperbilirubinemia due to peri-natal hemolytic disease
Others
If this option is checked, the prescriber must provide a 
justification for the use of human albumin.
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Sciences of the University of São Paulo and the University 
Hospital of the University of São Paulo (CAAE: 
65583017.8.3001.0076). Since the study offered minimal 
risk to the patients involved, the application of the 
Informed Consent Form (ICF) was dispensed.
RESULTS AND DISCUSSION
According to the pharmacy dispensing records, 
HA was dispensed for 46 patients between January and 
October 2017. The Pharmacy Division received 98 
requests in this period, with the request average number 
per patient being 2.1 ± 1.5, ranging from 1 to 7 requests 
per patient. This variation was observed because some 
patients received HA on more than one occasion, which is 
also reported in other studies (Matos, Rozenfeld, 2005). In 
addition, for indications where HA needed to be given for 
more than one day (e.g., spontaneous bacterial peritonitis 
or hepatorenal syndrome), it was not uncommon to present 
a request form for each day that HA would be given. 
Perhaps a modification in the “treatment time” field to fill 
in the request form will minimize this misinterpretation.
In HU-USP, the use of HA was common among 
adults (55; 56.1%) and pediatric patients (43; 43.9%) - 
as can be seen in Table II. The admission unit that most 
requested HA was PICU (28; 28.6%), followed by MC 
(24; 24.5%) and AER (19; 19.4%). This distribution is not 
related to the results found in other studies that analyzed 
the appropriate use of HA in their hospitals. This difference 
occurred mainly from the fact that the studies found in 
the literature were performed in tertiary and quaternary 
hospitals, so that the units that most requested HA in these 
hospitals were specialized units such as gastroenterology, 
cardiology and transplantation (Casuccio et al., 1998, 
Borges Filho et al., 2010, Vargas et al., 1997).
Analysis of the appropriate use of human albumin
Institutional protocol: therapeutic indication
The indications marked in the 98 requests are 
presented in Table III. 
From the results obtained in Table III it was 
possible to observe that 51 (52.0%) of the 98 requests 
marked the option “other” when requesting HA for the 
Pharmacy Division, mainly among pediatric patients. 
Other Brazilian studies have also shown that HA is 
frequently requested for other indications not included 
in the national guidelines (Borges Filho et al., 2010; 
Matos, Rozenfeld, 2005). However, in these studies, 
the rate of unsubstantiated indications was 28% and 
20.9%, respectively, with small or none contribution of 
pediatric patients. When only adult patients of the study 
are considered, the rate of unsubstantiated indications was 
14 (14.3%), becoming more similar to the rates found in 
the literature. Unfortunately, the scientific literature on the 
HA use in pediatric populations is scarce, which makes it 
impossible to compare them with the results found in the 
present study.
It is important to highlight that these 51 requests 
with the “other” option marked referred to 29 patients, of 
which 3 presented more than one request with different 
indications (“unquestionable” and “other”) in a short 
period (maximum of 3 days). These 3 patients were 
pediatric and the “unquestionable” indication was “ liver 
cirrhosis and nephrotic syndrome”, when there is diuretic-
refractory edema, that pose imminent risk to patients’ lives 
(massive pleural or pericardial effusion or ascites), while 
the indication “other” was related to “nephrotic syndrome”. 
This “duplicity” of choice (between “unquestionable” 
and “other” indications) was also observed in the study 
by Matos and Rozenfeld (2005), but the cause of this 
“duplicity” was not presented. In the present study, 
what was observed is an apparent contradiction, since 
a single disease (nephrotic syndrome) was between the 
“unquestionable” and “other” indications. One possible 
explanation for this finding was the specificity of the 
criteria for the use of HA in nephrotic syndrome to be 
considered unquestionable. According to RDC No. 115, 
dated May 10, 2004, the use of HA for this indication is 
only recommended for cases in which “there are edemas 
TABLE II - Requests for human albumin, per admission unit 
(HU-USP, from January to October 2017)
Unit N (%)
Adult 
(≥ 15 years)
MC 24 (24.5)
AER 19 (19.4)
CS 7 (7.1)
AICU 5 (5.1)
All 55 (56.1)
Pediatric 
(< 15 years)
PICU 28 (28.6)
PC 11 (11.2)
PER 2 (2.0)
NICU 2 (2.0)
All 43 (43.9)
Total 98 (100.0)
MC - Medical Clinic; AER - Adult Emergency Room; CS - 
Clinical Surgery; AICU - Adult Intensive Care Unit; PICU 
- Pediatric Intensive Care Unit; PC - Pediatric Clinic; PER - 
Pediatric Emergency Room; NICU - Neonatal Intensive Care 
Unit.
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that are refractory to diuretics and pose an imminent risk to 
patients’ lives (massive pleural effusions or pericardial or 
ascites)”. Therefore, for those patients that treatment was 
not refractory to diuretics or, in the prescriber’s evaluation 
was not characterized as a condition of imminent risk to 
patient’s life, the use of HA was not recommended, being 
included in the option “other “.
Therefore, due to the impossibility of verifying if 
the requests whose “other” option was marked and the 
justification related to the nephrotic syndrome respected 
the condition of refractoriness or life-threatening, the 
indication of HA for these requests was considered 
“inappropriate”. In addition, none of the other justifications 
could be supported by the protocol, and therefore all 
requests with the “other” option marked were considered 
“inappropriate”. Requests classified as “unregistered”, 
that is, those that had no indication marked in the request 
were also considered inappropriate. The final result of 
this classification, with the analysis of the appropriate 
indication of the HA according to the institutional protocol 
is presented in Table IV.
Clinical protocols published in the last years: 
therapeutic indication and dose regimen
The synthesis of the recommendations was 
performed with recommendations of five clinical protocols 
and is shown in Table V. Only the therapeutic indications 
in the requests of using HA in HU-USP are presented.
When searching medical records of the 46 patients 
who received HA during the study period, only 25 (54.3%) 
were available for consultation at the SMAS. Therefore, at 
this stage, the analysis was limited to 25 patients, resulting 
in 54 forms.
Analyzing the recommendations of the synthesis 
table, it was observed that, for some indications, the use 
of HA was conditioned. For example, according to the 
summary table the use of HA in cases of spontaneous 
bacterial peritonitis should be associated with the 
antibiotics use. Table VI presents these conditions of 
using. 
TABLE III - Indications marked in the request form for human albumin use (HU-USP, from January to October 2017)
Indications Adult N (%)
Pediatric 
N (%) N (%)
Unquestionable
Treatment of massive ascites by repeated paracentesis 3 (3.1) 0 (0.0) 3 (3.1)
After evacuation paracentesis in massive ascites 5 (5.1) 0 (0.0) 5 (5.1)
Hepatic cirrhosis and nephrotic syndrome, when there is diuretic-
refractory edema, that pose imminent risk to patients’ lives (massive 
pleural or pericardial effusion or ascites)
13 (13.3) 5 (5.1) 18 (18.4)
All 21 (21.5) 5 (5.1) 26 (26.6)
Debatable
In patients with cirrhosis and prevalence of spontaneous bacterial 
peritonitis 18 (18.4) 0 (0.0) 18 (18.4)
Newborn hyperbilirubinemia due to peri-natal hemolytic disease 
(HDN) 0 (0.0) 0 (0.0) 0 (0.0)
All 18 (18.4) 0 (0.0) 18 (18.4)
Others
Shock related (hypovolemic or septic) 1 (1.0) 27 (27.6) 28 (28.6)
Related to hepatorenal syndrome 10 (10.2) 0 (0.0) 10 (10.2)
Related to nephrotic syndrome 0 (0.0) 8 (8.2) 8 (8.2)
Related to anuria or oliguria 2 (2.1) 1 (1.0) 3 (3.1)
Related to edema or anasarca 1 (1.0) 1 (1.0) 2 (2.0)
All 14 (14.3) 37 (37.7) 51 (52.0)
Unregistered 2 (2.1) 1 (1.0) 3 (3.1)
Total 55 (56.1) 43 (43.9) 98 (100)
TABLE IV - Analysis of the appropriate therapeutic indications 
of human albumin according to the institutional protocol (HU-
USP, from January to October 2017)
Indications N (%)
Appropriate in relation to the institutional 
protocol
44 (44.9)
Inappropriate in relation to the institutional 
protocol
54 (55.1)
Total 98 (100)
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Table VII presents the comparison between the 
information found in the medical records and the presented 
conditions and the table of synthesis (Table V).
In other words, from Table VII it was possible to 
affirm that the conditions presented in Table VI were 
followed in all cases in which the HA use was indicated. 
This suitability rate was higher than that observed in 
other studies of the appropriate use of HA. The study 
TABLE V - Synthesis of recommendations for human albumin use
Indication Recommendation Dosing recommendation
Paracentesis
Small volume (< 4 or 5 liters) - Use crystalloids as 
first choice (University Hospital Consortium, 2010). 
If management of condition is refractory to sodium 
restriction (90mmol/day), HA may be considered 
(Liumbruno et al., 2009). In patients with cirrhosis: 
HA may be indicated as option if there are concerns 
regarding use of synthetic colloids or crystalloids 
(volume overload, renal failure, coagulopathy) 
(Stanford Health Care, 2017; Guy’s and St. Thomas’ 
NHS Foundation Trust, 2015; Caraceni et al., 2016).
Large volume (≥ 4 or 5 liters) – There is widespread 
consensus on the HA use (Vermeulen, Ratko, Erstad, 
2010; Liumbruno et al., 2009). In patients with 
cirrhosis: Should be use HA and avoid combinations 
with other plasma expanders to reduce the dose of HA. 
Consider oral midodrine or terlipressin, mainly in 
critical care (Guy’s and St. Thomas’ NHS Foundation 
Trust, 2015; Caraceni et al., 2016; National Plasma 
Products Expert Advisory Group - Scotland NHS, 
2016; Ontario Regional Blood Coordinating Network, 
2012).
20 g of albumin 20% per every 3L ascites 
drained or 20 g of albumin per every 2L if renal 
function impaired (Guy’s and St. Thomas’ 
NHS Foundation Trust, 2015; National Plasma 
Products Expert Advisory Group - Scotland 
NHS, 2016).
6 to 8 g of albumin 25% per every liter ascitic 
fluid removed (Vermeulen, Ratko, Erstad, 2010; 
Liumbruno et al., 2009; Stanford Health Care, 
2017; Caraceni et al., 2016).
Hepatorenal 
Syndrome (HRS)
For diagnosis of SuspectedA – HA may benefit. 
Diuretics use should be discontinued and considered 
volume expansion with HA for 2 consecutive days, 
then it should be evaluated if there was improvement 
of renal function (Vermeulen, Ratko, Erstad, 2010; 
Liumbruno et al., 2009; Stanford Health Care, 2017). 
In patients with cirrhosis: HA is used regularly 
(Caraceni et al., 2016).
ConfirmedB – HA may be clinically indicated after 72 
hours, nephrology and hepatology services should be 
consulted on the maintenance of the HA use. Should 
be used with vasoconstricting drugs (midodrine 
and octreotide) (Vermeulen, Ratko, Erstad, 2010; 
Liumbruno et al., 2009; Stanford Health Care, 2017; 
National Plasma Products Expert Advisory Group 
- Scotland NHS, 2016; Lyu et al.; 2016). Eligible 
for liver transplantation: HA should be used with 
vasoactive drugs, consider terlipressin (Guy’s and St. 
Thomas’ NHS Foundation Trust, 2015). In patients 
with cirrhosis: HA should be given with other 
vasoconstrictors (noradrenaline or midodrine plus 
octreotide) (Caraceni et al., 2016).
Suspected - 1 g/kg of albumin 25% (up to 100 g) 
daily for 2 consecutive days (Vermeulen, Ratko, 
Erstad, 2010; Stanford Health Care, 2017; Guy’s 
and St. Thomas’ NHS Foundation Trust, 2015; 
Caraceni et al., 2016).
Confirmed - Day 1: 1g/kg of albumin 5% or 
20%
Day 2 to 16: 20 to 40 g of albumin 5% or 20% 
daily (Vermeulen, Ratko, Erstad, 2010; National 
Plasma Products Expert Advisory Group - 
Scotland NHS, 2016)
Day 1: 1 g/kg of albumin 20% or 25%
Day 2 to14: 0.5 g/kg of albumin 20% or 
25% daily (Guy’s and St. Thomas’ NHS 
Foundation Trust, 2015; Ontario Regional Blood 
Coordinating Network, 2012).
Albumin should be given with vasoconstrictors 
(Caraceni et al., 2016; National Plasma Products 
Expert Advisory Group - Scotland NHS, 2016).
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Indication Recommendation Dosing recommendation
Spontaneous Bacterial 
Peritonitis (SBP)
HA may be used. Some authors recommend use of 
HA according clinical conditions (including patients 
with cirrhosis) (Vermeulen, Ratko, Erstad, 2010; 
Stanford Health Care, 2017; Guy’s and St. Thomas’ 
NHS Foundation Trust, 2015; National Plasma 
Products Expert Advisory Group - Scotland NHS, 
2016; Ontario Regional Blood Coordinating Network, 
2012).
Low-risk patientsC – decision on use of HA should be 
individualised; HA use could be restricted to “high” 
risk patients.
High-risk patients - HA administration is mandatory 
for patients with cirrhosis and is not recommended 
the use of crystalloids and synthetic colloids or 
association these with HA (Caraceni et al., 2016; 
National Plasma Products Expert Advisory Group - 
Scotland NHS, 2016).
Day 1: 1.5 g/kg of albumin 5%, 20% or 25%.
Day 3: 1 g/kg of albumin 5%, 20% or 25%. 
(Caraceni et al., 2016; National Plasma Products 
Expert Advisory Group - Scotland NHS, 2016).
Albumin should be given in association with 
antibiotics (Guy’s and St. Thomas’ NHS 
Foundation Trust, 2015).
Severe Nephrotic 
Syndrome
HA may be considered in cases with severe 
refractory edema or symptoms and signs of sub-acute 
intravascular volume depletion, including oliguria, 
poor peripheral perfusion, abdominal pain, raised 
creatinine and haematocrit; always under supervision 
of consultant paediatric nephrologist (Guy’s and St. 
Thomas’ NHS Foundation Trust, 2015).
1g/kg of albumin 20% over 6 hours, with or 
without loop diuretic (Guy’s and St. Thomas’ 
NHS Foundation Trust, 2015).
Maldistributive shock
Crystalloids should be considered first-line therapy 
(Vermeulen, Ratko, Erstad, 2010; National Plasma 
Products Expert Advisory Group - Scotland NHS, 
2016). Inappropriate use of HA (Stanford Health Care, 
2017). Maybe used in patients with refractory septic 
shock who have received resuscitation with crystalloid 
and require >0.2mcg/kg/min of norepinephrine (Guy’s 
and St. Thomas’ NHS Foundation Trust, 2015). 
Consider use of HA in critical care (Lyu et al., 2016).
Adults: 20 to 40 g of albumin over 30 to 
60 minutes (Guy’s and St. Thomas’ NHS 
Foundation Trust, 2015).
Children: Without evidence.
A – Suspected HRS: serum creatinine >1.5 mg/dL in the presence of cirrhosis, B – Confirmed HRS: i. serum creatinine >1.5 mg/dL 
in the presence of cirrhosis; ii. absence of shock, ongoing bacterial infection, and/or current treatment with nephrotoxic drugs; iii. 
absence of sustained improvement in renal function after discontinuation of diuretics and a trial of albumin 1 g/kg; iv. absence of 
proteinuria (<500 mg/day) or hematuria (<50 red cells per high-power field); v. absence of ultrasonographic evidence of obstructive 
uropathy or parenchymal renal disease. C - Low risk patients: baseline serum bilirubin <4 mg/dL and serum creatinine <1 mg/dL3. 
TABLE V - Synthesis of recommendations for human albumin use (cont.)
TABLE VI - Conditions for the use of HA according to other clinical protocols
Indication Recommendation
Paracentesis Volume of ascites fluid drained (> 4L)
Hepatorenal Syndrome Without evaluation criteria
Spontaneous Bacterial Peritonitis (SBP) Association with antibiotics
Nephrotic syndrome in children Refractory condition to diuretic use
Maldistributive shock Refractory condition to crystalloid use
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whose numbers approached most was an Italian study 
conducted in October 2013. According to this study, 
the indication suitability was observed in 83.3% of the 
requests (Casuccio et al., 2015).
When comparing the suitability rate of the therapeutic 
indications, according to the institutional protocol (Table 
IV), with the suitability rate of the therapeutic indications, 
according to other clinical protocols (Table VII), it is 
possible to observe a great divergence between the two 
suitability profiles. According to the RDC nº 115, the use 
of HA is considered inappropriate for maldistributive 
shock (volemic or septic) and hepatorenal syndrome. In 
the case of shock, the use of HA is still much debated in 
clinical practice, so its use is not yet recommended in 
many clinical protocols. This is because the use of HA as 
a volume expander in critically ill patients in septic shock 
is considered safe (Caraceni et al., 2015). However, when 
comparing the use of colloids (HA) and crystalloids as 
volume expander, no superiority was found in relation 
to the effectiveness of the colloid on the crystalloid, so 
that the crystalloid is recommended as a first choice 
solution because its lower cost and lower rate of adverse 
effects (Medeiros et al., 2015). However, in the case of 
hepatorenal syndrome, the use of HA is already considered 
a formal indication (Valerio et al., 2016; Bernardi, Ricci, 
Zaccherini, 2014). Thus, from the results obtained, it is 
possible to affirm that an updating of the institutional 
protocol is necessary, including septic shock as a condition 
in which HA is adequately indicated when the patient is 
refractory to crystalloids, and hepatorenal syndrome as an 
appropriate indication therapy for the use of HA. 
Regarding the dosage regimen, Table VIII presents 
the comparison between those found in medical records 
and the recommended in Table VI.
Different from the appropriateness of the indication 
profile presented in Table VIII, when the dosage 
regimen was analyzed, inappropriate use was observed 
in 16 (29.7%) requests. When searching for studies to 
compare the profile found, it was observed that, despite 
the inappropriate use of HA is widely discussed in the 
literature, no study has yet evaluated the types found. 
In the present study, inadequate dosage varied mainly 
in relation to the HA prescribed dose and the treatment 
time. In addition, in the case of septic shock, no guideline 
studied showed a definite dosage for the use of HA in 
children. However, databases such as Micromedex® 
and Lexicomp®, and references such as the Blackbook 
Pediatria, indicated the use of HA for this condition. The 
most frequently found dose was 1 g/kg. Given that the 
institutional protocol does not show dosage schedules 
in the HA request form, the present study proposes that 
when updating this protocol, the dosage regimens must 
be included.
Limitations and strengths of the study
Regarding the study limitations, it was performed 
in a university medium complexity hospital where the 
use of HA should not be very frequent. Thus, the profile 
TABLE VIII - Analysis of dosage regimens suitability, according 
to other clinical protocols (HU-USP, from January to October 
2017)
Dosage regimen N (%)
Appropriate 13 (24.1)
Maldistributive shock 9 (16.7)
Nephrotic syndrome in children 8 (14.8)
Spontaneous bacterial peritonitis (SBP) 5 (9.2)
High volume paracentesis 3 (5.5)
Suspicion of hepatorenal syndrome 38 (70.3)
All
Inappropriate 4 (7.4)
Spontaneous bacterial peritonitis (SBP) 4 (7.4)
Suspicion of hepatorenal syndrome 3 (5.6)
Maldistributive shock 3 (5.6)
Nephrotic syndrome in children 2 (3.7)
No indication of use 0 (0.0)
High volume paracentesis 16 (29.7)
All
Total 54 (100)
TABLE VII - Analysis of the appropriateness of therapeutic 
indications, according to other clinical protocols (HU-USP, from 
January to October 2017)
Indications N (%)
Appropriate
Maldistributive shock 16 (29.6)
Nephrotic syndrome in children 12 (22.2)
Spontaneous bacterial peritonitis (SBP) 12 (22.2)
Suspicion of hepatorenal syndrome 7 (13.0)
High volume paracentesis 5 (9.3)
Inappropriate
No indication of use 2 (3.7)
Total 54 (100)
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of HA use in the institution can be very particular, not 
being similar to the profile of use found in the literature. 
In addition, the review to seek information on albumin use 
in clinical protocols was not performed in a systematic 
manner, with evaluation of the documents quality. Finally, 
the unavailability of almost 50% of patient’s records 
reduced the sample size and may have affected the 
suitability rate of the therapeutic indications. 
On the other hand, the question of the rational use 
of albumin is still current and there are few studies of HA 
that include pediatric patients or the suitability of dose 
regimens. In addition, the fact that compliance with other 
clinical protocols is much higher than when comparing 
with the institutional protocol shows that prescribers are 
up to date with the evidence regarding the use of HA, 
which is expected in a university hospital. They are not 
linking their practice to the RDC, possibly because that 
document was published over 10 years ago and certainly 
needs to be updated.
CONCLUSION
The present study evaluated the appropriateness of 
the use of HA in relation to an institutional protocol based 
on Brazilian regulations and other clinical guidelines. We 
observed lack of updating of the institutional protocol, 
since it has been shown to play a fundamental role in the 
results observed as inappropriate. The major problem in 
HU/USP was the dose regimen. In addition, the University 
Hospital of the University of São Paulo (HU-USP) is a 
secondary hospital, and the use of HA should not be so 
frequent in the institution, since the studies presented 
on the use of HA report the use in high complexity 
hospitals (tertiary and quaternary), with specialties such 
as gastroenterology, cardiology and transplantation as the 
main requesters for HA in these institutions.
ACKNOWLEDGEMENT 
The authors would like to express their gratitude to 
the Ministry of Health and to the Ministry of Education 
for the financial support provided for this study and for 
the Pharmacy Residency Program of which one of the 
authors participates.
REFERENCES
Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in 
the management of complications of liver cirrhosis. J Clin Exp 
Hepatol. 2014;4(4):302-11.
Borges Filho WM, Almeida SM de, Ferracini FT, Fernandes 
Júnior CJ. Pharmacy contribution to the prescription and rational 
use of human albumin at a large hospital. Einstein (São Paulo). 
2010;8(2):215-20. 
Brasil. Ministério da Saúde. Agência Nacional de Vigilância 
Sanitária. Resolução RDC nº 115, de 10 de maio de 2004. 
Aprova as Diretrizes para o uso de Albumina. Diário Oficial da 
União, Brasília, DF, 11 maio 2004. [Internet] 2004. [cited 2017 
Dec 29] Available from: <http:// http://redsang.ial.sp.gov.br/site/
docs_leis/rs/rs12.pdf>
Caraceni P, Domenicali M, Tovoli A, Napoli L, Ricci CS, 
Tufoni M, et al. Clinical indications for the albumin use: Still a 
controversial issue. Eur J Intern Med. 2013;24(8):721-8.
Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. 
Blood Transfus. 2013;11(Suppl 4):s18-s25. 
Caraceni P, Angeli P, Prati D, Bernardi M, Alessandria C, Riggio 
O, et al. AISF-SIMTI Position Paper: The appropriate use of 
albumin in patients with liver cirrhosis. Dig Liver Dis. 2016 
Jan;48(1):4-15. 
Casuccio A, Nalbone E, Immordino P, Seta C La, Sanfilippo P, 
Tuttolomondo A, et al. Appropriateness of requests for human 
serum albumin at the University Hospital of Palermo, Italy: A 
prospective study. Int J Qual Heal Care. 2015;27(2):154-60. 
Corrêa TD, Rocha LL, Pessoa CMS, Silva E, Assunção MSC de. 
Fluid therapy for septic shock resuscitation: which fluid should 
be used? Einstein (São Paulo). 2015;13(3):462-8.
Guy’s and St. Thomas’ NHS Foundation Trust. Guideline for 
the use of human albumin solution (HAS). 2015. Available 
on: https://www.sps.nhs.uk/wp-content/uploads/2015/05/ 
Guideline20use20human20albumin20solution20and20 
demand20management20final.pdf 
Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, 
Rossetti G. Recommendations for the use of albumin and 
immunoglobulins. Blood Transfus. 2009;7(3):216-34.
Lyu PF, Hockenberry JM, Gaydos LM, Howard DH, Buchman 
TG, Murphy DJ. Impact of a Sequential Intervention on Albumin 
Utilization in Critical Care. Crit Care Med. 2016;44(7):1307-13.
Matos GC de, Rozenfeld S. Avaliação do uso de albumina 
humana em hospital do Rio de Janeiro, Brasil. Cad Saúde 
Pública. 2005;21(4):1224-33. 
T. S. Ishida, M. C. Sakai, D. O. Melo
Braz. J. Pharm. Sci. 2018;54(4):e18008Page 10 / 10
Medeiros DNM, Ferranti JF, Delgado AF, Carvalho WB de. 
Colloids for the initial management of severe sepsis and septic 
shock in pediatric patients: a systematic review. Pediatr Emerg 
Care. 2015;31(11):e11-6.
National Plasma Products Expert Advisory Group - Scotland 
NHS. Clinical guidelines for human albumin use. 2016. 
Available on: http://www.nsd.scot.nhs.uk/documents/
guidelines/albumingdl.pdf.
Ontario Regional Blood Coordinating Network. Ontario 
Albumin Administration Recommendations. 2012. Available on: 
http://www.nsd.scot.nhs.uk/documents/guidelines/albumingdl.
pdf.
Stanford Health Care. Guidelines for Intravenous Albumin 
Administration at Stanford Health Care. 2017. Available 
on: https://stanfordhealthcare.org/content/dam/SHC/health-
care-professionals/medical-staff/medstaff-weekly/20170315-
guidelines-for-intravenous-albumin-administration.pdf 
Vermeulen LC Jr, Ratko TA, Erstad BL. A paradigm for 
consensus: The University Hospital Consortium guidelines for 
the use of albumin, nonprotein colloid, and crystalloid solutions. 
Arch Intern Med. 1995 (revised 2005 & 2010);155:373-379. 
Available on: https://www.universityhealthsystem.com/~/
media/files/clinical-pathways/albumin-guidelines-0410.pdf.
Tullis JL. Albumin. 1.  Background and use.  JAMA. 
1977a;237(4):355-60
Tullis JL. Albumin. 2. Guidelines for clinical use. JAMA. 
1977b;237(5):460-3
Vaglio S, Calizzani G, Grazzini G, Lanzoni M, Liumbruno 
GM. Italian albumin usage (or misusage?). Eur J Intern Med. 
2014;25(3):e31-2
Valerio C, Theocharidou E, Davenport A, Agarwal B. Human 
albumin solution for patients with cirrhosis and acute on 
chronic liver failure: Beyond simple volume expansion. World 
J Hepatol. 2016;8(7):345-54. 
Vargas E, De Miguel V, Portolés A, Avendaño C, Ambit MI, 
Torralba A, et al. Use of albumin in two Spanish university 
hospitals. Eur J Clin Pharmacol. 1997;52(6):465-70.
Received for publication on 05th January 2018
Accepted for publication on 15th March 2018
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
